Friday, April 17, 2009

7:00 am
Breakfast

8:00 am
Welcome and introduction
James Armitage, MD – Chair
Jorge Cortes, MD – Chair
Robert Orlowski, MD, PhD – Chair
Jim Epstein, MD – Moderator

 

Hodgkin’s Lymphoma
8:10 am
Debate: Nodular lymphocyte predominant Hodgkin’s lymphoma

Conservative therapy
Speaker invited

Curative therapy
Kerry J. Savage, MD, MSc, FRCPC

 

Non-Hodgkin’s Lymphoma
8:40 am
Debate: What is the most appropriate second line therapy for a follicular lymphoma patient who received frontline R-CHOP and relapses 4 months after completing maintenance rituximab?

Bendamustine based therapy
Steven H. Bernstein, MD

Radioimmunotherapy
Stephen M. Ansell, MD, PhD

S tem Cell Transplant
Julie Vose, MD

9:15 am
Debate: Should the newly recognized biological sub-groups guide our treatment for diffuse large B-Cell Lymphoma?
No – Brian K. Link, MD
Yes – Craig Moskowitz, MD

9:45 am
Debate: Should all aggressive peripheral T-Cell lymphomas be treated in the same manner?
No – Julie Vose, MD
Yes – Steven M. Horwitz, MD

10:15 am
Coffee break

10:30 am
Debate: Should CLL/SLL sub-groups that have deletion 17p or who have the best prognostic features be treated differently than the average CLL/SLL patient?
No – William G. Wierda, MD, PhD
Yes – Michael E. Williams, MD

11:00 am
Debate: Is there still a role for “Watch & Wait“ in follicular lymphoma?
No – Speaker invited
Yes – John P. Leonard, MD

11:30 am
Lunch Lymphoma

12:15 pm
Symposium on Emerging Therapies in Lymphoproliferative Diseases: Monoclonal antibodies
Brian K. Link, MD

Proteasome inhibitors
John P. Leonard, MD

Syk inhibitors
Steven H. Bernstein, MD

mTOR inhibitors
Stephen M. Ansell, MD, PhD

Epigenetic targeted agents
Steven M. Horwitz, MD

BCL-2 inhibitors
William G. Wierda, MD, PhD

Immunomodulatory agents
Craig Moskowitz, MD

2:00 pm
Panel for Q & A – audience submitted questions

2:30 pm
Coffee break

 

Myeloma
2:50 pm
Don’t get blind-sided by Mr. MGUS – How to identify those MGUS patients most likely to progress to active Multiple Myeloma
S. Vincent Rajkumar, MD

3:20 pm
Debate: Is multiple myeloma curable without resorting to allogeneic SCT?
No – Sagar Lonial, MD
Yes – S.Vincent Rajkumar, MD

3:50 pm
Debate: Is CR/nCR the Holy Grail for front line therapy of myeloma?
No – Kenneth C. Anderson, MD
Yes – Rafael Fonseca, MD

4:20 pm
Novel therapies for multiple myeloma
Kenneth C. Anderson, MD

4:45 pm
Adjourn

Saturday, April 18, 2009

7:00 am
Breakfast

8:00 am
Welcome and introduction
James Armitage, MD – Chair
Jorge Cortes, MD – Chair
Robert Z. Orlowski, MD, PhD – Chair
Jim Epstein, MD – Moderator

8:10 am
Debate: Are alkylating agents still necessary components of front line therapy for older, transplant ineligible patients?
No – Robert Z. Orlowski, MD, PhD
Yes – Nikhil C. Munshi, MD

8:40 am
Should Auto-SCT be performed during the first remission or second remission – or does it matter?
Rafael Fonseca, MD

9:05 am
Debate: Is it possible to decide on the basis of available clinical and molecular prognostic factors for multiple myeloma whether a patient should receive front line therapy with an immunomodulatory compound or a proteasome inhibitor or both?
No – Nikhil C. Munshi, MD
Yes – Sagar Lonial, MD

9:35 am
Debate: Should the International Staging System that utilizes β2M and serum albumin be changed to include metaphase cytogenetic and FISH analyses?
No – Robert Z. Orlowski, MD, PhD
Yes – Rafael Fonseca, MD

10:05 am
Coffee break CML

10:25 am
Debate: Should younger patients who fail to achieve CCyR after 12 months of imatinib be referred for allogeneic-SCT or be given second generation TKIs?

Allogeneic-SCT
Speaker invited

Second generation TKIs
Michael J. Mauro, MD

10:55 am
Debate: What should be the frontline therapy for high risk newly diagnosed CML patients?

Imatinib (standard dose)
Michael J. Mauro, MD

Other options (high-dose imatinib, 2nd generation TKI, combinations)
Jorge Cortes, MD

11:25 am
Debate: What is significantly more clinically important - Complete Molecular Remission or Complete Cytogenetic Response?

Complete Molecular Remission
Speaker invited

Complete Cytogenetic Response
Jorge Cortes, MD

11:55 am
Lunch

 

MDS
1:00 pm
Debate: For a symptomatic 67 year old man with intermediate-1 MDS with Hgb=9.2, ANC=1300, and Platelet count=115,000 plus cytogenetic changes of deletion 5q plus deletion 2-q, what would be the most appropriate therapy – hypomethylating agents or immunomodulatory compounds?

Hypomethylating compounds
David P. Steensma, MD

Immunomodulatory compounds
Gail Roboz, MD

1:30 pm
Debate: Management of low risk MDS – Best Supportive Care versus hypomethylating agents

BSC
Gail Roboz, MD

Hypomethylating agents
David P. Steensma, MD

2:00 pm
Emerging Therapies for MDS
Stephen Nimer, MD

2:25 pm
Coffee break CLL

2:45 pm
Debate: Should molecular biomarkers or clinical prognostic factors be used to decide therapy for CLL patients?

Molecular biomarkers
Matt Kalaycio, MD

Clinical prognostic factors
Michael J. Keating, MB, BS

3:15 pm
Debate: What is the most appropriate therapy for CLL patients who relapse >12 months following induction therapy with a fludarabine-rituximab based regimen?

Alemtuzumab
Matt Kalaycio, MD

Purine analog-based therapy
Michael J. Keating, MB, BS

Bendamustine-based therapy
Ann F. Mohrbacher, MD

3 :45 pm
Adjourn